Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 173

1.

CSP-1103 (CHF5074) stabilizes human transthyretin in healthy human subjects.

Qiang L, Guan Y, Li X, Liu L, Mu Y, Sugano A, Takaoka Y, Sakaeda T, Imbimbo BP, Yamamura KI, Jin S, Li Z.

Amyloid. 2017 Apr 10:1-10. doi: 10.1080/13506129.2017.1308348. [Epub ahead of print]

PMID:
28393633
2.

Neuroprotective and Anti-Apoptotic Effects of CSP-1103 in Primary Cortical Neurons Exposed to Oxygen and Glucose Deprivation.

Porrini V, Sarnico I, Benarese M, Branca C, Mota M, Lanzillotta A, Bellucci A, Parrella E, Faggi L, Spano P, Imbimbo BP, Pizzi M.

Int J Mol Sci. 2017 Jan 18;18(1). pii: E184. doi: 10.3390/ijms18010184.

3.

Reversible Cognitive Frailty, Dementia, and All-Cause Mortality. The Italian Longitudinal Study on Aging.

Solfrizzi V, Scafato E, Seripa D, Lozupone M, Imbimbo BP, D'Amato A, Tortelli R, Schilardi A, Galluzzo L, Gandin C, Baldereschi M, Di Carlo A, Inzitari D, Daniele A, Sabbà C, Logroscino G, Panza F; Italian Longitudinal Study on Aging Working Group..

J Am Med Dir Assoc. 2017 Jan;18(1):89.e1-89.e8. doi: 10.1016/j.jamda.2016.10.012.

PMID:
28012505
4.

Bipolar Disorder and Frontotemporal Dementia: An Intriguing Association.

Papazacharias A, Lozupone M, Barulli MR, Capozzo R, Imbimbo BP, Veneziani F, De Blasi R, Nardini M, Seripa D, Panza F, Logroscino G.

J Alzheimers Dis. 2017;55(3):973-979.

PMID:
27802240
5.

Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients.

Panza F, Seripa D, Solfrizzi V, Imbimbo BP, Lozupone M, Leo A, Sardone R, Gagliardi G, Lofano L, Creanza BC, Bisceglia P, Daniele A, Bellomo A, Greco A, Logroscino G.

Expert Opin Emerg Drugs. 2016 Dec;21(4):377-391. Epub 2016 Oct 6. Review.

PMID:
27678025
6.

Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy.

Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Lozupone M, Santamato A, Tortelli R, Galizia I, Prete C, Daniele A, Pilotto A, Greco A, Logroscino G.

Immunotherapy. 2016 Sep;8(9):1119-34. doi: 10.2217/imt-2016-0019.

PMID:
27485083
7.

Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease.

Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Lozupone M, Santamato A, Zecca C, Barulli MR, Bellomo A, Pilotto A, Daniele A, Greco A, Logroscino G.

Biomed Res Int. 2016;2016:3245935. doi: 10.1155/2016/3245935. Epub 2016 Jun 26. Review.

8.

Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium.

Seripa D, Solfrizzi V, Imbimbo BP, Daniele A, Santamato A, Lozupone M, Zuliani G, Greco A, Logroscino G, Panza F.

Expert Rev Neurother. 2016;16(3):259-77. doi: 10.1586/14737175.2016.1140039. Review.

PMID:
26822031
9.

Examination of level of knowledge in Italian general practitioners attending an education session on diagnosis and management of the early stage of Alzheimer's disease: pass or fail?

Veneziani F, Panza F, Solfrizzi V, Capozzo R, Barulli MR, Leo A, Lozupone M, Fontana A, Arcuti S, Copetti M, Cardinali V, Grasso A, Tursi M, Iurillo A, Imbimbo BP, Seripa D, Logroscino G.

Int Psychogeriatr. 2016 Jul;28(7):1111-24. doi: 10.1017/S1041610216000041. Epub 2016 Jan 28.

PMID:
26817511
10.

Tau aggregation inhibitors: the future of Alzheimer's pharmacotherapy?

Panza F, Seripa D, Solfrizzi V, Imbimbo BP, Santamato A, Lozupone M, Capozzo R, Prete C, Pilotto A, Greco A, Logroscino G.

Expert Opin Pharmacother. 2016;17(4):457-61. doi: 10.1517/14656566.2016.1146686. Epub 2016 Feb 15. No abstract available.

PMID:
26809554
11.

Coffee Consumption Habits and the Risk of Mild Cognitive Impairment: The Italian Longitudinal Study on Aging.

Solfrizzi V, Panza F, Imbimbo BP, D'Introno A, Galluzzo L, Gandin C, Misciagna G, Guerra V, Osella A, Baldereschi M, Di Carlo A, Inzitari D, Seripa D, Pilotto A, Sabbá C, Logroscino G, Scafato E; Italian Longitudinal Study on Aging Working Group..

J Alzheimers Dis. 2015;47(4):889-99. doi: 10.3233/JAD-150333.

PMID:
26401769
12.

Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.

Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Santamato A, Lozupone M, Prete C, Greco A, Pilotto A, Logroscino G.

Expert Opin Pharmacother. 2015;16(17):2581-8. doi: 10.1517/14656566.2015.1092520. Epub 2015 Sep 21. Review.

PMID:
26389682
13.

Age-related hearing impairment and frailty in Alzheimer's disease: interconnected associations and mechanisms.

Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Capozzo R, Quaranta N, Pilotto A, Logroscino G.

Front Aging Neurosci. 2015 Jun 9;7:113. doi: 10.3389/fnagi.2015.00113. eCollection 2015. No abstract available.

14.

CHF5074 (CSP-1103) stabilizes human transthyretin in mice humanized at the transthyretin and retinol-binding protein loci.

Mu Y, Jin S, Shen J, Sugano A, Takaoka Y, Qiang L, Imbimbo BP, Yamamura K, Li Z.

FEBS Lett. 2015 Mar 24;589(7):849-56. doi: 10.1016/j.febslet.2015.02.020. Epub 2015 Feb 26.

15.

CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid.

Porrini V, Lanzillotta A, Branca C, Benarese M, Parrella E, Lorenzini L, Calzà L, Flaibani R, Spano PF, Imbimbo BP, Pizzi M.

Neuroscience. 2015 Aug 27;302:112-20. doi: 10.1016/j.neuroscience.2014.10.029. Epub 2014 Oct 22.

PMID:
25450955
16.

Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease.

Panza F, Solfrizzi V, Imbimbo BP, Giannini M, Santamato A, Seripa D, Logroscino G.

Expert Rev Neurother. 2014 Sep;14(9):973-86. doi: 10.1586/14737175.2014.945522. Epub 2014 Aug 1. Review.

PMID:
25081412
17.

Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?

Panza F, Solfrizzi V, Imbimbo BP, Logroscino G.

Expert Opin Biol Ther. 2014 Oct;14(10):1465-76. doi: 10.1517/14712598.2014.935332. Epub 2014 Jun 30. Review.

PMID:
24981190
18.

Pharmacological targeting of the β-amyloid precursor protein intracellular domain.

Branca C, Sarnico I, Ruotolo R, Lanzillotta A, Viscomi AR, Benarese M, Porrini V, Lorenzini L, Calzà L, Imbimbo BP, Ottonello S, Pizzi M.

Sci Rep. 2014 Apr 9;4:4618. doi: 10.1038/srep04618.

19.

Electrophysiological and metabolic effects of CHF5074 in the hippocampus: protection against in vitro ischemia.

Mango D, Barbato G, Piccirilli S, Panico MB, Feligioni M, Schepisi C, Graziani M, Porrini V, Benarese M, Lanzillotta A, Pizzi M, Pieraccini S, Sironi M, Blandini F, Nicoletti F, Mercuri NB, Imbimbo BP, Nisticò R.

Pharmacol Res. 2014 Mar;81:83-90. doi: 10.1016/j.phrs.2014.02.010. Epub 2014 Mar 12.

PMID:
24630950
20.

CHF5074 and LY450139 sub-acute treatments differently affect cortical extracellular glutamate levels in pre-plaque Tg2576 mice.

Beggiato S, Giuliani A, Sivilia S, Lorenzini L, Antonelli T, Imbimbo BP, Giardino L, Calzà L, Ferraro L.

Neuroscience. 2014 Apr 25;266:13-22. doi: 10.1016/j.neuroscience.2014.01.065. Epub 2014 Feb 12.

PMID:
24530449

Supplemental Content

Loading ...
Support Center